The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Here is a hard truth for those of us who are care providers: Americans are unsatisfied with the country's healthcare system.

On Tuesday, the U.S. Federal Trade Commission (FTC) presented evidence that UnitedHealth Group’s OptumRx, along with its two main competitors, Express Scripts and CVS Caremark Rx, inflated the ...

Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's ...

the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N CVS Caremark and Cigna's CI.N Express Scripts ...

and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

and UnitedHealth Group Inc.'s (UNH) Optum RX. The FTC report said the Big Three marked up prices for numerous specialty generic drugs, including those that treat cancer, heart disease and HIV ...

The updated tally extends the scope beyond what was previously described by company Chief Executive Andrew Witty.